DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers

Congratulations to DaiichiSankyo on the commencement of first-in-human trials of DS-3939, which has been developed using a humanized anti-TA-MUC1 antibody with carbohydrate mediated tumor-specificity and high affinity binding, licensed from Glycotope.

Press Release: Download here